The company said it recorded worldwide net revenues of $15.0 billion, operating earnings of $4.0 billion and diluted earnings per share of $0.39 for the 3 months ended March 31, 2026. Net revenues rose 12% on a reported basis and 10% on a constant currency basis.

10-QQuarterly reportFiled May 8, 2026Period of report Mar 31, 2026Summary published (UTC) Oct 2, 2026

Key points

AI summary

The company said it recorded worldwide net revenues of $15.0 billion, operating earnings of $4.0 billion and diluted earnings per share of $0.39 for the 3 months ended March 31, 2026. Net revenues rose 12% on a reported basis and 10% on a constant currency basis.
The company said its Q1 2026 results included amortization of intangible assets of $1.7 billion and a change in the fair value of contingent consideration liabilities of $2.4 billion. It said the fair value change reflected higher estimated Skyrizi sales and the passage of time, partially offset by higher discount rates.
AbbVie said net revenues for Skyrizi rose 29% and those for Rinvoq rose 20% in Q1 2026 on a constant currency basis, while Humira fell 40%. The company cited the continued impact of direct biosimilar competition following the loss of exclusivity as the reason for the Humira decline.
The company said operating cash flow for Q1 2026 was $3.8 billion, and it issued unsecured senior notes with an aggregate principal of $8.0 billion in financing activities. Over the same period, it paid cash dividends of $3.1 billion and repurchased 5 million shares for $1.1 billion.

Key figures

Quarter ended March 31, 2026

Revenue: $15.0B
Operating income: $4.0B
Net income: $695M
EPS: $0.39
Operating cash flow: $3.8B

From the XBRL financial data filed with the SEC · not processed by AI.

Summary

AI-written

Analysis scope · Management's discussion (MD&A)We analyzed the Management's Discussion and Analysis (MD&A) section. Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

Q1 2026 Net Revenues, Operating Earnings and Diluted EPS

The company said it recorded worldwide net revenues of $15.0 billion, operating earnings of $4.0 billion and diluted earnings per share of $0.39 for the 3 months ended March 31, 2026. Net revenues rose 12% on a reported basis and 10% on a constant currency basis.

Source · Based on the MD&A text of the filing

Amortization of Intangibles and Contingent Consideration Fair Value Changes

The company said its Q1 2026 results included amortization of intangible assets of $1.7 billion and a change in the fair value of contingent consideration liabilities of $2.4 billion. It said the fair value change reflected higher estimated Skyrizi sales and the passage of time, partially offset by higher discount rates.

Source · Based on the MD&A text of the filing

Net Revenues by Product (Constant Currency)

AbbVie said net revenues for Skyrizi rose 29% and those for Rinvoq rose 20% in Q1 2026 on a constant currency basis, while Humira fell 40%. The company cited the continued impact of direct biosimilar competition following the loss of exclusivity as the reason for the Humira decline.

Source · Based on the MD&A text of the filing

AbbVie Cash Flows and Shareholder Returns for Q1 2026

The company said operating cash flow for Q1 2026 was $3.8 billion, and it issued unsecured senior notes with an aggregate principal of $8.0 billion in financing activities. Over the same period, it paid cash dividends of $3.1 billion and repurchased 5 million shares for $1.1 billion.

Source · Based on the MD&A text of the filing

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.